172. 低ホスファターゼ症 Disease details / Clinical trials / Drug dev / DR info

ALXN1850
   Alexion Pharmaceuticals, Inc.
      2024   Phase 3   NCT06079372   Argentina;Australia;Canada;France;Germany;India;Italy;Japan;Turkey;United Kingdom;United States
      2024   Phase 3   NCT06079359   Argentina;Australia;Belgium;Brazil;Canada;China;Finland;France;Germany;Israel;Italy;Korea, Republic of;Mexico;Poland;Romania;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Vietnam
      2024   Phase 3   NCT06079281   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czechia;Finland;France;Germany;Greece;India;Israel;Italy;Japan;Korea, Republic of;Poland;Romania;Slovakia;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
      2021   Phase 1   NCT04980248   United States
   Wuebbenhorst Hiroaki
      2024   Phase 3   JPRN-jRCT2051230131   Argentina;Australia;Canada;France;Germany;Italy;Japan;Turkey;United Kingdom;United States of America
Asfotas alfa
   Alexion Pharma International Sàrl
      2016   Phase 4   EUCTR2015-000809-39-FR   Belgium;France;Netherlands;Russian Federation;Spain
Asfotase alfa
   Alexion Pharma GmbH
      2011   Phase 2   EUCTR2010-019850-42-DE   Australia;Canada;France;Germany;Italy;Japan;Russian Federation;Saudi Arabia;Spain;Taiwan;Turkey;United Kingdom;United States
   Alexion Pharma GmbH
      2016   Phase 2   EUCTR2015-003131-35-DE   Germany;United States
      2013   Phase 2   EUCTR2010-019850-42-GB   Australia;Canada;France;Germany;Italy;Japan;Russian Federation;Saudi Arabia;Spain;Taiwan;Turkey;United Kingdom;United States
      2009   Phase 2   EUCTR2009-009369-32-GB   United Arab Emirates;United Kingdom;United States
      -   Phase 2   EUCTR2017-003153-42-Outside-EU/EEA   Canada;United States
      -   Phase 2   EUCTR2017-001831-38-Outside-EU/EEA   Canada;United States
   Alexion Pharma International Sàrl
      2016   Phase 4   EUCTR2015-000809-39-FR   Belgium;France;Netherlands;Russian Federation;Spain
      2013   Phase 2   EUCTR2010-019850-42-IT   Argentina;Australia;Canada;France;Germany;Italy;Japan;Saudi Arabia;Spain;Taiwan;Turkey;United Kingdom;United States
      2013   Phase 2   EUCTR2010-019850-42-ES   Argentina;Australia;Canada;France;Germany;Italy;Japan;Saudi Arabia;Spain;Taiwan;Turkey;United Kingdom;United States
      -   -   EUCTR2015-001128-52-Outside-EU/EEA   Canada;United States
      -   Phase 2   EUCTR2010-019850-42-FR   Argentina;Australia;Canada;France;Germany;Italy;Japan;Saudi Arabia;Spain;Taiwan;Turkey;United Kingdom;United States
   Alexion Pharmaceuticals
      2020   Phase 4   NCT04189315   -
      2016   Phase 2   NCT02797821   Germany;United States
      2016   -   NCT02496689   France;United States
      2015   Phase 4   NCT02531867   -
      2010   Phase 2   NCT01203826   Canada;United States
      2010   Phase 2/Phase 3   NCT01176266   Australia;Canada;France;Germany;Italy;Japan;Russian Federation;Saudi Arabia;Spain;Taiwan;Turkey;United Kingdom;United States
      2010   Phase 2   NCT01163149   Canada;United States
      2009   Phase 2   NCT01205152   United Arab Emirates;United Kingdom;United States
      2009   Phase 2   NCT00952484   Canada;United States
      2008   Phase 1/Phase 2   NCT00744042   Canada;United Arab Emirates;United Kingdom;United States
      2008   Phase 1   NCT00739505   Canada;United States
   Alexion Pharmaceuticals, Inc.
      2024   Phase 3   NCT06079372   Argentina;Australia;Canada;France;Germany;India;Italy;Japan;Turkey;United Kingdom;United States
      2022   -   NCT05234567   United States
      2019   -   NCT04195763   United States
   HPP study group
      2014   -   JPRN-UMIN000014816   Japan
   Translational Research Informatics Center, Kobe, Hyogo, Japan
      2014   Phase 2   NCT02456038   Japan
   Wuebbenhorst Hiroaki
      2024   Phase 3   JPRN-jRCT2051230131   Argentina;Australia;Canada;France;Germany;Italy;Japan;Turkey;United Kingdom;United States of America
Bioelectrical impedance analysis
   University of Bonn
      2023   -   NCT06161142   Germany
Bortezomib
   Alexion Pharmaceuticals, Inc.
      2025   Phase 4   NCT06015750   France;United Kingdom;United States
BPS804
   Novartis Pharma Services AG
      2011   -   EUCTR2010-024013-31-DE   Germany
   Ultragenyx Pharmaceutical Inc
      2011   Phase 2   NCT01406977   Germany
Cyclophosphamide
   Shimane University School of Medicine
      2010   Phase 2,3   JPRN-UMIN000003828   Japan
ENB-0040
   Alexion
      2009   Phase 2   NCT00894075   United States
   Alexion Pharma International Sàrl
      2016   Phase 4   EUCTR2015-000809-39-FR   Belgium;France;Netherlands;Russian Federation;Spain
      2013   Phase 2   EUCTR2010-019850-42-IT   Argentina;Australia;Canada;France;Germany;Italy;Japan;Saudi Arabia;Spain;Taiwan;Turkey;United Kingdom;United States
      2013   Phase 2   EUCTR2010-019850-42-ES   Argentina;Australia;Canada;France;Germany;Italy;Japan;Saudi Arabia;Spain;Taiwan;Turkey;United Kingdom;United States
      -   Phase 2   EUCTR2010-019850-42-FR   Argentina;Australia;Canada;France;Germany;Italy;Japan;Saudi Arabia;Spain;Taiwan;Turkey;United Kingdom;United States
   Enobia Canada Limited Partnership
      2009   -   EUCTR2008-007406-11-GB   United Kingdom
Extended laboratory diagnostics
   University of Bonn
      2023   -   NCT06161142   Germany
Folic acid
   Alexion Pharmaceuticals, Inc.
      2025   Phase 4   NCT06015750   France;United Kingdom;United States
Fully human IGG2 lambda monoclonal antibody
   Novartis Pharma Services AG
      2011   -   EUCTR2010-024013-31-DE   Germany
Genetic testing OF THE alkaline phosphatase gene
   University of Bonn
      2023   -   NCT06161142   Germany
Human recombinant tissue NON-specific alkaline phosphatase fusion protein
   Alexion Pharma GmbH
      2011   Phase 2   EUCTR2010-019850-42-DE   Australia;Canada;France;Germany;Italy;Japan;Russian Federation;Saudi Arabia;Spain;Taiwan;Turkey;United Kingdom;United States
   Alexion Pharma GmbH
      2016   Phase 2   EUCTR2015-003131-35-DE   Germany;United States
      2013   Phase 2   EUCTR2010-019850-42-GB   Australia;Canada;France;Germany;Italy;Japan;Russian Federation;Saudi Arabia;Spain;Taiwan;Turkey;United Kingdom;United States
      2009   Phase 2   EUCTR2009-009369-32-GB   United Arab Emirates;United Kingdom;United States
      -   Phase 2   EUCTR2017-003153-42-Outside-EU/EEA   Canada;United States
      -   Phase 2   EUCTR2017-001831-38-Outside-EU/EEA   Canada;United States
   Alexion Pharma International Sàrl
      2016   Phase 4   EUCTR2015-000809-39-FR   Belgium;France;Netherlands;Russian Federation;Spain
      2013   Phase 2   EUCTR2010-019850-42-IT   Argentina;Australia;Canada;France;Germany;Italy;Japan;Saudi Arabia;Spain;Taiwan;Turkey;United Kingdom;United States
      2013   Phase 2   EUCTR2010-019850-42-ES   Argentina;Australia;Canada;France;Germany;Italy;Japan;Saudi Arabia;Spain;Taiwan;Turkey;United Kingdom;United States
      -   -   EUCTR2015-001128-52-Outside-EU/EEA   Canada;United States
      -   Phase 2   EUCTR2010-019850-42-FR   Argentina;Australia;Canada;France;Germany;Italy;Japan;Saudi Arabia;Spain;Taiwan;Turkey;United Kingdom;United States
   Enobia Canada Limited Partnership
      2009   -   EUCTR2008-007406-11-GB   United Kingdom
Ilofotase alfa, 0.8 MG/KG
   AM-Pharma
      2023   Phase 1/Phase 2   NCT05890794   Germany
Ilofotase alfa, 3.2 MG/KG
   AM-Pharma
      2023   Phase 1/Phase 2   NCT05890794   Germany
Ivig
   Alexion Pharmaceuticals, Inc.
      2025   Phase 4   NCT06015750   France;United Kingdom;United States
Methotrexate
   Alexion Pharmaceuticals, Inc.
      2025   Phase 4   NCT06015750   France;United Kingdom;United States
   Shimane University School of Medicine
      2010   Phase 2,3   JPRN-UMIN000003828   Japan
Microindentation
   Hvidovre University Hospital
      2019   -   NCT04181164   Denmark
Physical examination
   University of Bonn
      2023   -   NCT06161142   Germany
Recording OF vital signs
   University of Bonn
      2023   -   NCT06161142   Germany
Retrospective case only
   Alexion Pharmaceuticals
      2014   -   NCT02235493   United States
Rituximab
   Alexion Pharmaceuticals, Inc.
      2025   Phase 4   NCT06015750   France;United Kingdom;United States
Second alkaline phosphatase measurement
   University of Bonn
      2024   -   NCT06574282   Germany
      2023   -   NCT06161142   Germany
SF-36
   University of Bonn
      2023   -   NCT06161142   Germany
Short physical performance battery (sppb) score
   University of Bonn
      2023   -   NCT06161142   Germany
Strensiq
   Alexion Pharma GmbH
      2011   Phase 2   EUCTR2010-019850-42-DE   Australia;Canada;France;Germany;Italy;Japan;Russian Federation;Saudi Arabia;Spain;Taiwan;Turkey;United Kingdom;United States
   Alexion Pharma GmbH
      2016   Phase 2   EUCTR2015-003131-35-DE   Germany;United States
      2013   Phase 2   EUCTR2010-019850-42-GB   Australia;Canada;France;Germany;Italy;Japan;Russian Federation;Saudi Arabia;Spain;Taiwan;Turkey;United Kingdom;United States
      2009   Phase 2   EUCTR2009-009369-32-GB   United Arab Emirates;United Kingdom;United States
      -   Phase 2   EUCTR2017-003153-42-Outside-EU/EEA   Canada;United States
      -   Phase 2   EUCTR2017-001831-38-Outside-EU/EEA   Canada;United States
   Alexion Pharma International Sàrl
      2016   Phase 4   EUCTR2015-000809-39-FR   Belgium;France;Netherlands;Russian Federation;Spain
Symptom and clinical findings checklist FOR hypophosphatasia
   University of Bonn
      2023   -   NCT06161142   Germany
Teriparatide
   Shanghai Sixth People's Hospital
      2024   -   ChiCTR2500099011   China
Whole genome sequencing
   Children's Mercy Hospital Kansas City
      2021   -   NCT05062629   United States